FAST NEWS: JW Therapeutics to expand collaboration with 2Seventy Bio
The latest: Drug maker JW (Cayman) Therapeutics Co. Ltd. (2126.HK) said on Tuesday it is in talks to expand its strategic alliance with 2Seventy Bio (TSVT.US), which began with a partnership established in…
FAST NEWS: JW Therapeutics’ loss narrows on lower selling expenses
The latest: Biotech company JW (Cayman) Therapeutics Co. Ltd. (2126.HK) reported on Tuesday its net loss for the first half of 2023 narrowed 11.4% year-on-year to 380 million yuan ($52.1 million). Looking…
FAST NEWS: JW Therapeutics’ revenue soars on growing lymphoma drug sales
The latest: Biotech company JW (Cayman) Therapeutics Co. Ltd. (2126.HK) said on Wednesday its revenue surged 373% to 146 million yuan ($21.2 million) last year, while its non-GAAP net loss narrowed…
FAST NEWS: Henlius Lung Cancer Drug Gets ‘Orphan’ Status in Europe
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Thursday its self-developed small cell lung cancer drug Hansizhuang has been granted orphan drug status by the European Commission (EC).Looking up:…
FAST NEWS: JW Therapeutics Announces Two Major Senior Appointments
The latest: Immunotherapy products maker JW (Cayman) Therapeutics Co. Ltd. (2126.HK) announced two major new appointments, including Dr. Shaun Paul Cordoba as its chief scientific officer and Raymond J. Hage…
Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale
The Chinese cancer drug maker’s shares surged on news of approval for its core product, only to return to earth after early investor Temasek exited Key takeaways: • Less than…
Recent Articles
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- IPO pitch puts BrainAurora’s earnings under the microscope
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
BRIEF: Qyuns Therapeutics secures CSRC approval for full H-share circulation
2509.HK
